Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM6YI5T)

Drug Name
Tegobuvir Drug Info
Synonyms
Tegobuvir; 1000787-75-6; UNII-5NOK5X389M; 5-((6-(2,4-bis(Trifluoromethyl)phenyl)pyridazin-3-yl)methyl)-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine; 5NOK5X389M; GS-9190; GS-333126; W-204340; 5H-Imidazo[4,5-c]pyridine, 5-[[6-[2,4-bis(trifluoromethyl)phenyl]-3-pyridazinyl]methyl]-2-(2-fluorophenyl)-;5H-Imidazo[4,5-c]pyridine, 5-[[6-[2,4-bis(trifluoromethyl)phenyl]-3-pyridazinyl]methyl]-2-(2-fluorophenyl)-; Tegobuvir [USAN:INN]; GS 9190; Tegobuvir (USAN/INN); GS 333126; SCHEMBL496778; CHEMBL1957287; DTXSID80142917
Cross-matching ID
PubChem CID
23649154
ChEBI ID
CHEMBL1957287
CAS Number
CAS 1000787-75-6
TTD Drug ID
D09RVI

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Rheumatoid arthritis 2.28 0.00e+0 78/93 (83.87%) HLA-DQA1;CXCL8;CCL20;...
VEGF signaling pathway 2.20 0.00e+0 50/59 (84.75%) CDC42;VEGFA;PIK3R1;...
TNF signaling pathway 2.05 0.00e+0 103/112 (91.96%) CASP10;TNFAIP3;CCL20;...
Chemokine signaling pathway 1.93 1.26e-2 163/192 (84.9%) SHC1;CXCL8;ITK;...
Non-alcoholic fatty liver disease 1.93 1.01e-2 126/155 (81.29%) CXCL8;CYCS;COX6B1;...
Oxidative phosphorylation 1.93 8.41e-3 93/133 (69.92%) COX6B1;ATP5PD;NDUFS4;...
T cell receptor signaling pathway 1.92 7.21e-3 93/104 (89.42%) RASGRP1;ITK;CDC42;...
Th1 and Th2 cell differentiation 1.91 7.88e-3 80/92 (86.96%) HLA-DQA1;IL2RG;HLA-DMB;...
Intestinal immune network for IgA production 1.84 1.54e-2 38/48 (79.17%) HLA-DQA1;HLA-DMB;CXCL12;...
Natural killer cell mediated cytotoxicity 1.84 1.39e-2 99/131 (75.57%) TNFSF10;SHC1;PIK3R1;...
Necroptosis 1.83 1.26e-2 113/159 (71.07%) CHMP6;GLUL;TNFSF10;...
Morphine addiction 1.81 2.00e-2 80/91 (87.91%) PDE4B;ARRB2;PRKACB;...
Type I diabetes mellitus 1.80 1.94e-2 38/43 (88.37%) HLA-DQA1;HLA-DMB;CD86;...
Allograft rejection 1.80 1.80e-2 32/38 (84.21%) HLA-DQA1;HLA-DMB;CD86;...
Citrate cycle (TCA cycle) 1.80 1.77e-2 30/30 (100%) ACLY;DLD;IDH2;...
Viral protein interaction with cytokine and cytokine re... 1.79 1.73e-2 84/100 (84%) TNFSF10;CXCL8;IL2RG;...
Nitrogen metabolism 1.77 2.15e-2 16/17 (94.12%) GLUL;GLUD1;GLUD2;...
Graft-versus-host disease 1.77 2.10e-2 32/42 (76.19%) HLA-DQA1;HLA-DMB;CD86;...
Leukocyte transendothelial migration 1.75 2.66e-2 90/114 (78.95%) ITK;CLDN7;CDC42;...
Retrograde endocannabinoid signaling 1.73 3.15e-2 118/148 (79.73%) PRKACB;ITPR1;NDUFS4;...
IL-17 signaling pathway 1.72 3.18e-2 84/94 (89.36%) CXCL8;IKBKE;TNFAIP3;...
Inflammatory bowel disease 1.72 3.10e-2 58/65 (89.23%) HLA-DQA1;IL2RG;HLA-DMB;...
Autoimmune thyroid disease 1.68 3.78e-2 46/53 (86.79%) HLA-DQA1;HLA-DMB;TSHR;...
PD-L1 expression and PD-1 checkpoint pathway in cancer 1.68 3.73e-2 79/89 (88.76%) RASGRP1;BATF3;CD3E;...
Fc epsilon RI signaling pathway 1.65 4.29e-2 57/68 (83.82%) PIK3R1;MAP2K6;LCP2;...
Th17 cell differentiation 1.65 4.32e-2 95/107 (88.79%) HLA-DQA1;IL2RG;HLA-DMB;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 3H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.04uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H